Select a medication above to begin.
Soltamox
tamoxifen
Black Box Warnings .
Uterine Malignancies and Thromboembolic Events
serious, life-threatening, and sometimes fatal events in risk reduction setting (ductal carcinoma in situ and high breast CA risk women) incl. uterine malignancies (endometrial adenocarcinoma and uterine sarcoma), stroke, and PE; discuss potential benefits and risks of tx w/ women in these populations considering decr. breast CA risk; tamoxifen benefits outweigh risks in women already diagnosed w/ breast CA
Adult Dosing .
Dosage forms: SOL: 20 mg per 10 mL
hormone receptor-positive breast CA
- [adjuvant tx]
- Dose: 20 mg PO qd x5-10y; Max: 20 mg/day; Info: for use following total/partial mastectomy, axillary dissection, and breast XRT and to decr. CA risk in contralateral breast
- [metastatic dz]
- Dose: 20-40 mg/day PO divided qd-bid; Info: for male and female metastatic breast CA tx; divide dose bid if >20 mg/day
ductal CA in situ (DCIS)
- [20 mg PO qd x5y]
- Info: for use following breast surgery and XRT to decr. invasive breast CA risk
breast CA prevention
- [20 mg PO qd x5y]
- Info: for high risk women
mastalgia (off-label)
- [10 mg PO qd x4mo]
ovulation induction (off-label)
- [5-40 mg PO bid x4 days]
renal dosing
- [no adjustment]
- renal impairment: no adjustment
- HD: no adjustment; no supplement; PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: SOL: 20 mg per 10 mL
precocious puberty (off-label)
- [2-10 yo]
- Dose: 20 mg PO qd; Info: for female pts w/ McCune-Albright syndrome
renal dosing
- [not defined]
- renal impairment: consider adult renal dosing for guidance
- HD/PD: consider adult renal dosing for guidance
hepatic dosing
- [not defined]